Home › Companies › Intellia Therapeutics, Inc. › 2025-2026

Intellia Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Intellia Therapeutics, Inc.’s Form 8-K, filed 2026-06-10 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
327Asset managers
1,433Fund votes
2026-06-09Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Intellia Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Intellia Therapeutics, Inc.

These tallies are Intellia Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-10 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Intellia Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-09
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Muna Bhanji, R.Ph.	57,065,465	1,610,941	62,082	--	30,124,178	Majority: yes
Elect Director: Brian Goff	46,090,644	12,582,130	65,714	--	30,124,178	Majority: yes
Elect Director: Jesse Goodman, M.D., M.P.H.	43,004,221	15,686,289	47,978	--	30,124,178	Majority: yes

Source: Intellia Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-10 — read the filing on EDGAR.

How asset managers voted at the Intellia Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 327 asset managers that disclosed a Intellia Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Intellia Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Approval, on a non-binding advisory basis, of the compensation of our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

77% fund support · no official result

FOR 77%AGAINST 23%

The 311 asset managers below cast 77% of the shares they voted on this item FOR (42,281,130 for, 12,584,106 against).

FOR: 42,281,130 (77.1%)AGAINST: 12,584,106 (22.9%)ABSTAIN: 350 (0.0%)NOT VOTED: 4,228 (0.0%)

Largest asset managers voting on “Approval, on a non-binding advisory basis, of the compensation of our named executive officers.” at Intellia Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	11,992,892	0	For
Vanguard	9,377,035	9,838	For
BlackRock	4,090,936	52,170	For
REGENERON PHARMACEUTICALS, INC.	3,702,995	0	For
JUPITER ASSET MANAGEMENT LTD	0	2,084,131	Against
Amova Asset Management Co., Ltd.	0	1,970,512	Against
Contrarius Group Holdings Ltd	1,899,595	0	For
Charles Schwab	1,885,021	0	For
Two Sigma	0	1,668,531	Against
State Street	1,288,957	9,088	For
Federated Hermes	1,131,067	0	For
STIFEL NICOLAUS & CO INC \MO\	0	1,022,573	Against
ARK Investment Management LLC	941,616	0	For
Fidelity	619,247	100	For
Northern Trust	0	557,608	Against
SEI	491,716	916	For
Goldman Sachs	439,977	12,228	For
RBC Capital Markets, LLC	0	445,498	Against
Dimensional	0	378,627	Against
Vestmark Advisory Solutions, Inc.	375,746	0	For
First Trust	2,016	302,678	Against
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	0	278,910	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	269,242	Against
AMERICAN BEACON FUNDS	263,406	0	For
WASATCH ADVISORS LP	0	261,555	Against

Showing the 25 largest of 311 asset managers. See all 311 in the interactive database.

2. Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Muna Bhanji, R.Ph.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 57,065,465AGAINST: 1,610,941

Intellia Therapeutics, Inc.’s own tally for this item (“Elect Director: Muna Bhanji, R.Ph.”): 57,065,465 for, 1,610,941 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 120,447,521 outstanding shares: 47.4% for, 1% against (48.7% of the company cast a for/against vote).

The 69 asset managers below cast 99% of the shares they voted on this item FOR (27,778,831 for, 338,951 against).

FOR 99%

FOR: 27,778,831 (98.8%)AGAINST: 338,951 (1.2%)

Largest asset managers voting on “Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of ” at Intellia Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	11,992,892	0	For
Vanguard	8,468,850	6,895	For
BlackRock	1,811,468	0	For
Charles Schwab	942,278	0	For
Federated Hermes	537,475	0	For
Fidelity	364,717	0	For
State Street	363,145	463	For
First Trust	300,652	0	For
AMERICAN BEACON FUNDS	263,406	0	For
WASATCH FUNDS TRUST	255,347	0	For
Dimensional	0	240,234	Against
ARK Venture Fund	235,077	0	For
TIAA	220,858	0	For
Equitable	155,988	64,000	For
QUANTITATIVE MASTER SERIES LLC	180,135	0	For
SEI	167,927	0	For
JPMorgan	152,589	0	For
TANAKA FUNDS INC	124,000	0	For
ProShares	108,988	0	For
Goldman Sachs	107,515	0	For
American Century	87,753	0	For
SEI Exchange Traded Funds	84,067	0	For
Lincoln Financial	76,387	4,839	For
Global X	64,653	0	For
WESMARK FUNDS	64,000	0	For

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

3. Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Brian Goff

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST 21%

FOR: 46,090,644AGAINST: 12,582,130

Intellia Therapeutics, Inc.’s own tally for this item (“Elect Director: Brian Goff”): 46,090,644 for, 12,582,130 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 120,447,521 outstanding shares: 38% for, 10% against (48.7% of the company cast a for/against vote).

The 69 asset managers below cast 96% of the shares they voted on this item FOR (26,852,614 for, 1,265,167 against).

FOR 96%

FOR: 26,852,614 (95.5%)AGAINST: 1,265,167 (4.5%)

Largest asset managers voting on “Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of ” at Intellia Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	11,992,892	0	For
Vanguard	8,475,700	45	For
BlackRock	1,811,468	0	For
Charles Schwab	942,278	0	For
Federated Hermes	537,475	0	For
Fidelity	364,617	100	For
State Street	363,190	418	For
First Trust	0	300,652	Against
AMERICAN BEACON FUNDS	263,406	0	For
WASATCH FUNDS TRUST	255,347	0	For
Dimensional	0	240,234	Against
ARK Venture Fund	235,077	0	For
TIAA	220,858	0	For
Equitable	155,988	64,000	For
QUANTITATIVE MASTER SERIES LLC	180,135	0	For
SEI	167,927	0	For
JPMorgan	152,589	0	For
TANAKA FUNDS INC	124,000	0	For
ProShares	0	108,988	Against
Goldman Sachs	107,515	0	For
American Century	0	87,753	Against
SEI Exchange Traded Funds	84,067	0	For
Lincoln Financial	76,387	4,839	For
Global X	64,653	0	For
WESMARK FUNDS	0	64,000	Against

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

4. Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, or until their earlier death, resignation or removal: Jesse Goodman, M.D., M.P.H.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST 27%

FOR: 43,004,221AGAINST: 15,686,289

Intellia Therapeutics, Inc.’s own tally for this item (“Elect Director: Jesse Goodman, M.D., M.P.H.”): 43,004,221 for, 15,686,289 against, per its Form 8-K filed 2026-06-10 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 120,447,521 outstanding shares: 36% for, 13% against (48.7% of the company cast a for/against vote).

The 69 asset managers below cast 91% of the shares they voted on this item FOR (25,510,805 for, 2,606,976 against).

FOR 91%9%

FOR: 25,510,805 (90.7%)AGAINST: 2,606,976 (9.3%)

Largest asset managers voting on “Election of three class I directors to our board of directors, each to serve until the 2029 annual meeting of ” at Intellia Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	11,992,892	0	For
Vanguard	8,465,396	10,349	For
BlackRock	1,811,468	0	For
Charles Schwab	0	942,278	Against
Federated Hermes	537,475	0	For
Fidelity	364,617	100	For
State Street	362,727	881	For
First Trust	0	300,652	Against
AMERICAN BEACON FUNDS	263,406	0	For
WASATCH FUNDS TRUST	255,347	0	For
Dimensional	0	240,234	Against
ARK Venture Fund	235,077	0	For
TIAA	220,858	0	For
Equitable	155,988	64,000	For
QUANTITATIVE MASTER SERIES LLC	180,135	0	For
SEI	0	167,927	Against
JPMorgan	152,589	0	For
TANAKA FUNDS INC	124,000	0	For
ProShares	0	108,988	Against
Goldman Sachs	107,515	0	For
American Century	0	87,753	Against
SEI Exchange Traded Funds	0	84,067	Against
Lincoln Financial	76,387	4,839	For
Global X	0	64,653	Against
WESMARK FUNDS	0	64,000	Against

Showing the 25 largest of 69 asset managers. See all 69 in the interactive database.

5. RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 68 asset managers below cast 99.9% of the shares they voted on this item FOR (27,993,765 for, 15 against).

FOR: 27,993,765 (100.0%)AGAINST: 15 (0.0%)

Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ” at Intellia Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
ARK ETF Trust	11,992,892	0	For
Vanguard	8,475,743	1	For
BlackRock	1,811,468	0	For
Charles Schwab	942,278	0	For
Federated Hermes	537,475	0	For
Fidelity	364,717	0	For
State Street	363,594	14	For
First Trust	300,652	0	For
AMERICAN BEACON FUNDS	263,406	0	For
WASATCH FUNDS TRUST	255,347	0	For
Dimensional	240,234	0	For
ARK Venture Fund	235,077	0	For
TIAA	220,858	0	For
Equitable	219,988	0	For
QUANTITATIVE MASTER SERIES LLC	180,135	0	For
SEI	167,927	0	For
JPMorgan	152,589	0	For
ProShares	108,988	0	For
Goldman Sachs	107,515	0	For
American Century	87,753	0	For
SEI Exchange Traded Funds	84,067	0	For
Lincoln Financial	81,226	0	For
Global X	64,653	0	For
WESMARK FUNDS	64,000	0	For
Direxion Shares ETF Trust	52,483	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

78% fund support · no official result

FOR 78%AGAINST 22%

The 5 asset managers below cast 78% of the shares they voted on this item FOR (1,672 for, 481 against).

FOR: 1,672 (77.7%)AGAINST: 481 (22.3%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Intellia Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Convergence Investment Partners, LLC	1,470	0	For
TD Waterhouse Canada Inc.	0	281	Against
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	202	0	For
LOUISBOURG INVESTMENTS INC.	0	200	Against
Torrey Growth & Income Advisors	0	0	--

7. 14A Executive Compensation

COMPENSATION

0.3% fund support · no official result

AGAINST 99.7%

The 2 asset managers below cast 0.3% of the shares they voted on this item FOR (160 for, 63,177 against).

FOR: 160 (0.3%)AGAINST: 63,177 (99.7%)

Largest asset managers voting on “14A Executive Compensation” at Intellia Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Orchard Capital Management, LLC	0	63,177	0	0	Against
PEDDOCK CAPITAL ADVISORS, LLC	160	0	0	0	For

8. To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (150 for, 0 against).

FOR: 150 (100.0%)

Largest asset managers voting on “To Approve, By An Advisory Vote, The Compensation Of The Company's Named Executives” at Intellia Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Modern Wealth Management, LLC	75	0	0	0	For
Tandem Financial, LLC	75	0	0	0	For

Largest Intellia Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Intellia Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 120,447,521 shares outstanding at the time of that meeting.

Top Intellia Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	ARK ETF Trust	9.96%
2	Vanguard	7.79%
3	BlackRock	3.44%
4	REGENERON PHARMACEUTICALS, INC.	3.07%
5	JUPITER ASSET MANAGEMENT LTD	1.73%
6	Amova Asset Management Co., Ltd.	1.64%
7	Contrarius Group Holdings Ltd	1.58%
8	Charles Schwab	1.57%
9	Two Sigma	1.39%
10	State Street	1.08%

Reported Intellia Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Intellia Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
ARK Investment Management LLC	11.80%	13G
Vanguard Group	10.80%	13F
BlackRock	10.09%	13F
State Street	5.75%	13F
Vanguard Portfolio Management	5.20%	13G
D.E. Shaw	4.76%	13F
Two Sigma	3.91%	13F
Morgan Stanley	1.93%	13F
Dimensional Fund Advisors	1.92%	13F
FMR (Fidelity)	1.72%	13F

Percentages above are of 120,447,521 shares outstanding, as reported by Intellia Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Intellia Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Intellia Therapeutics, Inc.'s shareholder meeting held 2026-06-09, in the 2025-2026 proxy season, 327 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,433 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Intellia Therapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — Approval, on a non-binding advisory basis, of the compensation of our named executive officers. — the reporting funds cast 77% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Intellia Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).